Coya Therapeutics has announced the initiation of the blinded extension phase of the ALSTARS trial.

Patients who complete the 24-week placebo-controlled double-blind phase enter the blinded extension phase of the study and continue on their regimen from the first phase; placebo patients are re-randomised to receive one of the two pre-specified dosing regimens of COYA 302 for a total of 24-weeks to provide a total of up to 48 weeks of data on COYA 302.

Fred Grossman, DO, FAPA, President and Chief Medical Officer (CMO), Coya, said, “We are very pleased with the progress of this important clinical study of COYA 302 in people with ALS that we hope may ultimately lead to a transformational new treatment. We would like to thank the patients, families, and caregivers for their ongoing support and contribution to the ALSTARS Trial.”